

SUBCUTANEOUS TRAMADOL INFILTRATION AT THE WOUND SITE VERSUS
INTRAVENOUS ADMINISTRATION AFTER INGUINAL HERNIA OPERATIONS^{*1}Dr. Mohammed Niyazi Ghani, ²Dr. Luqman Mohammed Azeez, ³Dr. Janan Wadea Hurmiz Zora¹M.B.Ch.B, F.I.B.M.S., F.K.B.M.S-GI & HPB Surgery, Rizgary Teaching Hospital /Erbile- Trainer in Arabic Board of General Surgery.²M.B.Ch.B-FICMS/ Rizgary Teaching Hospital-Erbil, Iraq.³M.B.Ch.B., F.I.B.M.S. "General Surgery", F.K.B.M.S "Digestive Surgery/ Rizgary Teaching Hospital-Erbil, Iraq.

Article Received: 08 October 2025

Article Revised: 29 October 2025

Article Published: 01 November 2025

***Corresponding Author: Dr. Mohammed Niyazi Ghani**

M.B.Ch.B, F.I.B.M.S., F.K.B.M.S-GI & HPB Surgery, Rizgary Teaching Hospital /Erbile- Trainer in Arabic Board of General Surgery.

DOI: <https://doi.org/10.5281/zenodo.17542132>**How to cite this Article:** ^{*1}Dr. Mohammed Niyazi Ghani, ²Dr. Luqman Mohammed Azeez, ³Dr. Janan Wadea Hurmiz Zora (2025). Subcutaneous Tramadol Infiltration At The Wound Site Versus Intravenous Administration After Inguinal Hernia Operations. Journal of Advance Healthcare Research, 9(11), 148–154.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Background and Objectives: One of the most dreaded and likely most common pain disorders is postoperative pain, which is frequently still not appropriately addressed. Our goal is to evaluate the analgesic efficacy and side effects of intravenous tramadol against local wound infiltration in adult patients following open inguinal hernia surgeries. **Patients And Methods:** Fifty adult male patients were randomly assigned to two groups; SC group (n=25) received tramadol 2 mg/kg titrated with NaCl 0.9% for a total of 20 mL, as a local wound infiltration prior to skin closure and IV group (n=25) received tramadol 2 mg/kg plus NaCl 0.9% to a volume of 50 mL was infused slowly within 15 minutes prior to skin closure. Postoperatively; pain severity, time to first analgesic requirement, analgesic consumption, and incidence of nausea & vomiting were recorded. **Results:** Over the course of the investigation, the IV group's VAS ratings were higher. The results showed that these scores were extremely significant at 3 hours and up to 24 hours ($p = 0.00$). Only one case (4.0%) in the SC group and four cases (16.0%) in the IV group needed diclofenac. Over the course of the trial, nausea and vomiting were less common in the SC group (p value = 0.00). **Conclusions:** In comparison to intravenous administration following open inguinal hernia procedures, subcutaneous wound infiltration of tramadol results in fewer cases of nausea and vomiting and a lower consumption of postoperative analgesics.

KEYWORDS: Inguinal Hernia, Intravenous administration, Subcutaneous Infiltration, Tramadol, Wound site.

INTRODUCTION

Postoperative pain after inguinal hernia repair negatively impacts recovery, with pain control affecting functional recovery speed. Subcutaneous wound-site infiltration of tramadol differs from intravenous administration, providing anesthesia in a non-opioid manner. Post-operative analgesia can be administered via intravenous (IV) tramadol or subcutaneous wound-site infiltration of tramadol. Both methods are equally effective but differ in pharmacokinetic profile and safety. Cross-reference to pharmacokinetics is justified for this comparison.^[1,2]

Postoperative pain is a significant risk factor for chronic inguinal pain after inguinal hernia repair. Controlling postoperative pain is crucial for optimal rehabilitation of

patients undergoing groin surgery. It is especially important during the early hours after surgery, when pain levels are at their peak, as severe pain can lead to chronic inguinal pain. Therefore, all measures must be taken to eliminate postoperative pain.^[3]

Because tramadol is a centrally acting opioid, its pharmacology for parenteral administration of tramadol is poorly documented. The main objective of this study was to compare postoperative analgesia following subcutaneous infiltration of tramadol 2 mg/kg at the suture line with tramadol 2 mg/kg given intravenously (IV) on immediate postoperative pain and recovery in patients undergoing inguinal hernia repair. The hypothesis was that tramadol would exert an analgesic

effect at wound sites where tissue damage occurred after surgery when compared to intravenous administration. Tramadol after 8–12 hours sedative effect is expected following surgical wound infiltration. The goal of the study was to evaluate the effect of wound-site infiltration.^[4]

Tramadol is a centrally acting atypical opioid analgesic that acts as a μ -opioid agonist and inhibits serotonin and norepinephrine reuptake.^[5] Tramadol is an analgesic agent that binds and activates μ -opioid receptors, weakly inhibiting norepinephrine and serotonin re-uptake. It is subject to significant liver metabolism, resulting in a systemic bioavailability of approximately 70%. Tramadol is marketed as parenteral formulation in 73 countries, with doses of 50 mg or 100 mg administered 4–6 hours apart. The intravenous route is the most widely adopted for parenteral tramadol.^[6]

Wound infiltration techniques provide effective regional analgesia with minimal systemic exposure, making them beneficial in medical settings. When combined with tramadol, this method enhances the overall analgesic effect and provides longer-lasting support during the recovery phase. Local infiltration during hernia repair reduces incision-related pain, allowing patients to resume normal activities more quickly. Regional infiltration may reduce the need for rescue analgesics, such as tramadol, in the early postoperative period, particularly during the first 0 to 6 hours after wound-site infiltration adjustment. However, this method does not alter the effectiveness of clinical outcomes achieved in the subsequent hours following the infiltration process.^[7]

Postoperative pain after inguinal hernia repair is continuous and can be managed effectively. Tramadol, an analgesic with fewer side effects, can help return to preoperative activity. Subcutaneous infiltration at the surgical wound site prolongs the interval before supplementary analgesics are needed, preventing local wound dependency.^[8]

Inguinal hernia repair and groin surgery are common procedures worldwide, affecting both adults and children. Postoperative pain control allows for quicker return to preoperative activity, facilitating early ambulation, which is crucial for uneventful meniscus healing.^[9,10]

Tramadol is a promising alternative to conventional analgesics due to its fewer adverse effects and lower abuse potential. Oral administration at moderate doses can provide postoperative comfort, especially in reconstruction surgery with an adductor tenotomy. Parenteral administration is often preferred due to its fast effect and systemic side, making it a popular choice for large volumes in practice.^[11] The current study aimed to compare the therapeutic effects and possible complications of intravenous versus local wound

infiltration of tramadol following open inguinal hernia operations.

PATIENTS AND METHODS

A comparative prospective study was carried out in the surgical units of both Erbil Teaching Hospital and Rizgari Teaching Hospital. All adult male patients of the American Society of Anesthesiologists physical status I–II, who underwent inguinal hernia repair under general anesthesia, during the period from September 2019 till March 2020, were enrolled in the study. Exclusion criteria; were patients with definitive liver disease (eg, acute and chronic hepatitis, cirrhosis, hemochromatosis); renal impairment (acute and chronic renal failure, glomerulonephritis); history of opium addiction and allergy to tramadol; history of seizure disorder; or administration of monoamine oxidase inhibitors, naloxone, cimetidine, carbamazepine, and ondansetron, and patients refusing general anesthesia were excluded from the study. The operations done by more than one surgeon and the type of the operations selected according to the surgeons preference. Patients were allocated randomly into one of two groups.

- **Subcutaneous group (SC)** (n=25): received subcutaneous wound infiltration contained tramadol 2 mg/kg titrated with NaCl 0.9% for a total of 20 mL. The infiltration started from the external oblique aponeurosis up to the skin prior to skin closure.
- **Intravenous group (IV)** (n=25): tramadol 2 mg/kg plus NaCl 0.9% to a volume of 50 mL was infused slowly within 15 minutes prior to skin closure.

We used Tramadol Hexal AG (Bach No. 8M1031) in both group.

Intravenous administration performed by the anesthesiologist while subcutaneous wound infiltration with tramadol done by the surgeon or by assistant.

Postoperative assessment of the intensity of pain as measured by a 10- mm visual analog scale (VAS) (Figure 1), and complications such as nausea and vomiting were recorded at time of receiving the patients in the ward (Regarded as zero time), after 30 minutes, hourly for six hours then at 12 hour and 24 hour postoperatively. Diclofenac 75mg/dose was administered intramuscular if pain intensity was greater than 4 and intravenous metoclopramide 10 mg/dose was prescribed if nausea and vomiting were present.




Figure 1: Visual Analog Scale (V A S)^[47]

Data Management and Statistical Analysis

1. The data were collected and entered into SPSS version 17.0 to generate the general characteristics of the study.

Parametric tests (T-test) were used for comparison between the results of the two groups. P value less than 0.05 was considered significant.

2. Each entry was double checked to avoid any possible mistakes.

3. Graphs and tables were drawn to summarize & present the results.

RESULTS

Fifty patients were included in the study, including 25 in SC group and 25 in IV group. Two patients in SC group & 3 patients in IV group initially assigned were excluded due to incomplete data collection. The age of patients in SC group ranged between 18-71 (mean 35.96) years and weight 42-104 (mean 68.48) Kg (figure 2), while in IV group age ranged between 18-69 (mean 39.67) years and weight between 48-90 (mean 65.32) Kg (Figure 3).




Figure (2): Age and weight of subcutaneous group.




Figure (3): Age and weight of intravenous group.

The mean differences in VAS, in each group during the study period are recorded. The VAS score at zero time was 0.28 ± 0.61 in the SC group and 0.6 ± 0.5 in the IV group. The VAS score was reported to be higher in the

IV group throughout the study. These scores were found to be highly significant at 3hr & up ward till 24hr ($p = 0.00$). (Table 1 & Figure 4).

Table (1): Comparison of the changes in the VAS scores during the study.

VAS Parameter	SC $\pm$ SD	IV $\pm$ SD	P value	Mean difference	95% C.I
zero time	0.28 ± 0.61	0.6 ± 0.5	0.04	-0.32	-0.63; -0.00
30 mint	0.8 ± 0.70	1.12 ± 0.52	0.07	-0.32	-0.67; -0.03
1hr	1.20 ± 0.81	1.20 ± 0.91	1.0	0.00	-0.49; 0.49
2hr	0.96 ± 0.88	1.12 ± 0.66	0.47	-0.16	0.60; 0.28
3hr	0.96 ± 0.53	1.36 ± 0.48	0.00	-0.40	-0.69; -0.10
4hr	1.04 ± 0.35	1.36 ± 0.56	0.02	-0.32	-0.58; -0.05
5hr	1.12 ± 0.33	1.56 ± 0.50	0.00	-0.44	-0.68; -0.19
6hr	1.20 ± 0.40	1.68 ± 0.55	0.00	-0.48	-0.75; -0.20
12hr	1.28 ± 0.45	1.68 ± 0.55	0.00	-0.40	-0.68; -0.11
24hr	1.28 ± 0.45	1.68 ± 0.55	0.00	-0.40	-0.68; -0.11

*Independent t-test for two means




Figure (4): Mean pain severity (VAS) in each group (repeated measures analysis with comparing factor; IV = intravenous administration; SC = subcutaneous wound infiltration; VAS = visual analog scale.

Only 1(4.0%) case in SC group & 1(4.0%) case in IV group were required diclofenac in the first 1-7 hr, and 3(12.0%) cases in IV group between 8-16hr. it was not

significant from statistical point of view ($p=0.20$) as shown in (Table 2).

Table (2): Diclofenac requirement in both groups.

Route of giving tramadol	Time of given Diclofenac		Total
	Between 1-7hr	Between 8-16hr	
SC	1	0	1
	4.0%	0.0%	4.0%
IV	1	3	4
	4.0%	12.0%	16.0%
Total	2	3	5
	4.0%	6.0%	10.0%

Considering groups, nausea and vomiting were frequently reported during the first hours of recovery; the complications, however, were less frequent 6 hours after the operations. Nausea and vomiting occurred less

frequently in the SC group throughout the study period, statically was highly significant ($p= 0.00$), as shown in (Table 3).

Table 3: The incidence of nausea & vomiting in both groups.

Time	Subcutaneous	Intravenous	P value*
at zero time	0(0%)	1(4%)	0.31
30mint	0(0%)	1(4%)	0.31
1hr	0(0%)	4(16%)	0.03
2hr	0(0%)	1(4%)	0.31
3hr	0(4%)	1(4%)	0.31
4hr	1(4%)	1(4%)	1.0
5hr	0(0%)	1(4%)	0.31
6hr	1(4%)	0(0%)	0.31
12hr	0(0%)	0(0%)	
24hr	0(0%)	0(0%)	
Total	2(8%)	10(40%)	0.008

DISCUSSION

Of all the pain syndromes, postoperative pain is one of the most dreaded and most likely to occur, but it is frequently still not well addressed. Despite being the standard for treating acute pain, opioids are nevertheless feared by patients, nurses, and doctors.^[12] After major surgery, postoperative discomfort increases hospital stays, postoperative morbidity, and recovery time.^[13] Additionally, the most prevalent patient issue is postoperative discomfort. The degree of early postoperative pain and postoperative complications, particularly infectious complications, are positively correlated, according to a growing body of research.^[14] Greater rates of postoperative complications and greater degrees of postoperative pain are linked to more involved and involved surgical procedures.^[14,15] Even yet, several studies have shown that local anesthetic injections into surgical incisions are helpful.^[16-18] Due to the possibility of central nervous system and cardiovascular system toxicity, the effects of an unintentional local anesthetic injection might be fatal.^[19] The great prevalence of negative consequences, however, encourages research for substitutes. Recent research has demonstrated that localized usage of these medications can resolve the related issues.^[20,21] According to clinical research, tramadol produces a local anesthetic effect with no sedation or cardiovascular damage.^[22-24]

Following inguinal hernia procedures, we showed in this study that subcutaneous wound infiltration with tramadol is linked to a decreased incidence of nausea and vomiting, a decreased requirement for diclofenac (even no diclofenac within the first 24 hours in 90% of cases), and a drop in VAS ratings. Using analgesics like tramadol during surgery has been shown in several trials to reduce the requirement for analgesics after the procedure.^[25-27] when major abdominal surgery, Bayoumi et al.^[28] and Martinez et al.^[29] saw a significant reduction in morphine intake when tramadol was administered. Due to its capacity to reduce the need for postoperative analgesia, tramadol has been suggested by Costa et al.^[22] and Jendi and Talathi study^[30] as a potential substitute for lidocaine in small procedures. Gebremedhin et al.^[31] discovered that postoperative analgesia was sustained and the requirement for further

opioids was significantly decreased after subcutaneous wound infiltration with tramadol.

In our study, the group that got tramadol subcutaneous wound infiltration had a lower postoperative desire for analgesia. This observation indicates that tramadol infiltration into subcutaneous wounds is more effective, maybe as a result of its simultaneous systemic and local actions. After coronary artery bypass surgery, Martinez et al.^[29] were unable to find any appreciable variations in VAS, morphine intake, or antiemetic need after administering oral slow-release tramadol (150 mg every 12 hours). When compared to the use of a single medicine provided by a single approach, Weber et al.^[32] randomized experiment has demonstrated that multimodal analgesia is linked with greater pain relief and lower opioid intake.

CONCLUSION

Tramadol infusion into the subcutaneous incision causes less nausea and vomiting and less postoperative analgesic use than intravenous treatment following open inguinal hernia surgeries.

Recommendations

After all open inguinal hernia surgeries on adult patients, we advise applying subcutaneous tramadol wound infiltration.

REFERENCES

1. Minkowitz H, Salazar H, Leiman D, Solanki D, Lu L, Reines S, et al. Intravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial. *Drugs R D*, 2020 Sep; 20(3): 225-236. doi:10.1007/s40268-020-00309-0.
2. Donati PA, Tarragona L, Franco JV, Kreil V, Fravega R, Diaz A, et al. Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis. *Veterinary anaesthesia and analgesia*, 2021 May 1; 48(3): 283-96.
3. Olsson A, Sandblom G, Franneby U, Sondén A, Gunnarsson U, Dahlstrand U. Do postoperative complications correlate to chronic pain following inguinal hernia repair? A prospective cohort study

- from the Swedish Hernia Register. *Hernia.*, 2023 Feb; 27(1): 21-9.
4. Köckerling F, Schug-Pass C. Early Surgical Intervention following Inguinal Hernia Repair with Severe Postoperative Pain. *Front Surg.*, 2017 Nov 30; 4: 67. doi:10.3389/fsurg.2017.00067.
 5. Minkowitz H, Leiman D, Lu L, Reines S, Ryan M, Harnett M, et al. IV Tramadol - A New Treatment Option for Management of Post-Operative Pain in the US: An Open-Label, Single-Arm, Safety Trial Including Various Types of Surgery. *J Pain Res.*, 2020 May 22; 13: 1155-1162. doi:10.2147/JPR.S251175.
 6. Lu L, Ryan M, Harnett M, Atiee GJ, Reines SA. Comparing the Pharmacokinetics of 2 Novel Intravenous Tramadol Dosing Regimens to Oral Tramadol: A Randomized 3-Arm Crossover Study. *Clin Pharmacol Drug Dev.*, 2020 May; 9(4): 537-546. doi:10.1002/cpdd.746. Epub 2019 Oct 14.
 7. Stamenkovic DM, Bezmarevic M, Bojic S, Unic-Stojanovic D, Stojkovic D, Slavkovic DZ, et al. Updates on Wound Infiltration Use for Postoperative Pain Management: A Narrative Review. *Journal of Clinical Medicine.*, 2021; 10(20): 4659. https://doi.org/10.3390/jcm10204659
 8. Edinoff AN, Kaplan LA, Khan S, Petersen M, Sauce E, Causey CD, et al. Full opioid agonists and tramadol: pharmacological and clinical considerations. *Anesthesiology and Pain Medicine.*, 2021 Sep 6; 11(4): e119156.
 9. O'Brien J, Sinha S, Turner R. Inguinal hernia repair: a global perspective. *ANZ journal of surgery.*, 2021.
 10. Abebe MS, Tareke AA, Alem A, Debebe W, Beyene A. Worldwide magnitude of inguinal hernia: Systematic review and meta-analysis of population-based studies. *SAGE Open Medicine.*, 2022 Nov; 10: 20503121221139150.
 11. Nakhaee S, Hoyte C, Dart RC, Askari M, Lamarine RJ, Mehrpour O. A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment. *Forensic Toxicology.*, 2021 Jul; 39(2): 293-310.
 12. Gao L, Mu H, Lin Y, Wen Q, Gao P. Review of the Current Situation of Postoperative Pain and Causes of Inadequate Pain Management in Africa. *J Pain Res.*, 2023; 16: 1767-1778. https://doi.org/10.2147/JPR.S405574
 13. Ruohoaho UM, Aaltomaa S, Kokki H, Anttila M, Kokki M. Patient functional recovery after a 23-h surgery - a prospective, follow-up study. *Langenbecks Arch Surg.*, 2022; 407(5): 2133-2142. doi:10.1007/s 00423-022-02502-y
 14. Albers KI, van Helden EV, Dahan A, Martini CH, Brintjes MH, Scheffer GJ, et al. Early postoperative pain after laparoscopic donor nephrectomy predicts 30-day postoperative infectious complications: a pooled analysis of randomized controlled trials. *Pain.*, 2020 Jul 1; 161(7): 1565-70. doi:10.1097/j.pain.0000000000001842
 15. Helden EV, Kranendonk J, Vermulst A, de Boer A, de Reuver P, Rosman C, et al. Early postoperative pain and 30-day complications following major abdominal surgery: a retrospective cohort study *Regional Anesthesia & Pain Medicine.*, 2025; 50: 651-657.
 16. Bethenod F, Ellouze O, Berthoud V, Missaoui A, Cransac A, Aho S, et al. A single dose of tramadol in continuous wound analgesia with levobupivacaine does not reduce post-sternotomy pain: a randomized controlled trial. *J Pain Res.*, 2019; 12: 2733-2741. https://doi.org/10.2147/JPR.S211042
 17. Iversen J, Jermyn K, Dockray E, Eastwood M, Rotne R. Efficacy of locally infiltrated tramadol compared to bupivacaine during elective ovariohysterectomy procedures in canine patients: A double-blinded randomized parallel study. *Research in Veterinary Science.*, 2025; 188: 105611. https://doi.org/10.1016/j.rvsc.2025.105611
 18. Bhat HA, Rasool T, Mir AH, Ahmad T, shafi N. A Prospective Randomized Controlled Study to Compare The Postoperative Analgesic Effectiveness of Intra-peritoneal Instillation of Bupivacaine, Tramadol and Combination of Both in Lap Cholecystectomy. *Int J Acad Med Pharm.*, 2025; 7(2): 512-516. DOI:10.47009/jamp.2025.7.2.104
 19. Manouchehri A, Nekoukar Z, Malakian A, Zakariaei Z. Tramadol poisoning and its management and complications: a scoping review. *Ann Med Surg (Lond).*, 2023; 85(8): 3982-3989. doi:10.1097/MS9.000000000 0001075
 20. Shah J, Nair AB, Shah H, Jacob S, Shehata TM, Morsy MA. Enhancement in antinociceptive and anti-inflammatory effects of tramadol by transdermal proniosome gel. *Asian Journal of Pharmaceutical Sciences.*, 2020; 15(6): 786-796. https://doi.org/10.1016/j. ajps.2019.05.001
 21. Đanić P, Salarić I, Macan D. New Findings on Local Tramadol Use in Oral Surgery. *Acta Stomatol Croat.*, 2017; 51(4): 336-344. doi:10.15644/asc51/4/9
 22. Costa GL, Spadola F, Di Pietro S, et al. Tramadol vs. Lidocaine Administered Intraperitoneally and in Incisional Lines for the Intraoperative and Postoperative Pain Management of Romifidine-Telazol-Anesthetized Swine Undergoing Umbilical Hernia Repair. *Animals (Basel).*, 2023; 13(18): 2905. doi:10.3390/ani13182905
 23. Mansour RF and Afandy ME. Effect of tramadol as a local anesthetic adjuvant in epidural labor analgesia: Randomized controlled. *Egyptian Journal of Anaesthesia.*, 2020; 37(1): 1-8. https://doi.org/10.1080/11101849.2020.186 2986
 24. Madem A, Parusha S, Mallem D, Pacharla I, Kotra V, Chooi WH, et al. Comparing the Effect of Intravenous Tramadol and Intravenous Nalbuphine in Addition to Midazolam for the Control of Shivering after Spinal Anesthesia. *Journal of Pharmacology and Pharmacotherapeutics.*, 2024; 15(3): 264-276. doi:10.1177/0976500X241262076

25. Nešković N, Marci S, Mandić D, et al. ANALGESIC EFFECT OF TRAMADOL IS NOT ALTERED BY POSTOPERATIVE SYSTEMIC INFLAMMATION AFTER MAJOR ABDOMINAL SURGERY. *Acta Clin Croat.*, 2021; 60(2): 268-275. doi:10.20471/acc.2021.60.02.13
26. Bacanakgil BH, Kaban I. Tramadol for Early Postoperative Analgesia in Abdominal Hysterectomy: Comparison of Different Administration Techniques. *Istanbul Med J.*, 2021 Apr 22; 22(2): 120-124. doi:10.4274/imj.galenos.2021.62333.
27. Rashad AE, El Hefnawy E, Elmorshedi MA, Abuyousif YA, Salem A, El NakeebA, et al. The Effect of Intraoperative Tramadol on Post-Operative Opioid Requirements After Laparoscopic Sleeve Gastrectomy for Morbidly Obese Patients: A Retrospective Multicentric Cohort Study., 2024; 1-10. DOI:10.21608/ASJA.2024.250571.1014
28. Bayoumi HM, Abdelaziz DH, El Said NO, Boraii S, Bendas ER. Postoperative pain management following laparoscopic cholecystectomy-non-opioid approaches: A review. *Future Journal of Pharmaceutical Sciences.*, 2024; 10(1): 1-31. <https://doi.org/10.1186/s43094-024-00697-z>
29. Martinez V, Guichard L, Fletcher D. Effect of combining tramadol and morphine in adult surgical patients: a systematic review and meta-analysis of randomized trials. *BJA.*, 2015; 114(3): 384-395.
30. Jendi SK, Talathi A. Tramadol hydrochloride: An alternative to conventional local anaesthetics for intraoral procedures- a preliminary study. *Journal of Oral Biology and Craniofacial Research.*, 2018; 9(1): 111-114. <https://doi.org/10.1016/j.jobcr.2018.11.002>
31. Gebremedhin TD, Obsa MS, Andebirku AA, Gemechu AD, Haile KE, Zemedkun A. Local wound infiltration with a mixture of tramadol and bupivacaine versus bupivacaine alone in those undergoing lower abdominal surgery: Prospective cohort study, 2020. *International Journal of Surgery Open.*, 2022; 44: 100508. <https://doi.org/10.1016/j.ijso.2022.100508>
32. Weber L, Yeomans DC, Tzabazis A. Opioid-induced hyperalgesia in clinical anesthesia practice: what has remained from theoretical concepts and experimental studies? *Curr Opin Anaesthesiol.*, 2017; 30(4): 458–65.